Skin n Skin Past Earnings Performance
Past criteria checks 0/6
Skin n Skin has been growing earnings at an average annual rate of 6%, while the Chemicals industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.5% per year.
Key information
6.0%
Earnings growth rate
38.5%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | -14.5% |
| Return on equity | -41.6% |
| Net Margin | -40.0% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Skin n Skin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 15,565 | -6,219 | 9,764 | 292 |
| 31 Mar 24 | 13,932 | -7,157 | 9,720 | 292 |
| 31 Dec 23 | 13,924 | -7,217 | 8,695 | 292 |
| 30 Sep 23 | 5,736 | -10,628 | 7,462 | 253 |
| 30 Jun 23 | 6,737 | -11,114 | 8,171 | 253 |
| 31 Mar 23 | 9,788 | -9,832 | 7,401 | 253 |
| 31 Dec 22 | 13,262 | -8,277 | 6,329 | 253 |
| 30 Sep 22 | 20,254 | -898 | 5,476 | 66 |
| 30 Jun 22 | 25,595 | 2,371 | 3,672 | 122 |
| 31 Mar 22 | 30,400 | 2,853 | 3,447 | 179 |
| 31 Dec 21 | 27,612 | 1,711 | 3,633 | 240 |
| 30 Sep 21 | 29,778 | -7,805 | 19,411 | 177 |
| 30 Jun 21 | 26,618 | -9,683 | 20,464 | 120 |
| 31 Mar 21 | 23,690 | -10,016 | 19,892 | 143 |
| 31 Dec 20 | 25,282 | -7,429 | 19,021 | 223 |
| 30 Sep 20 | 26,658 | -4,478 | 5,559 | 296 |
| 30 Jun 20 | 23,615 | -4,788 | 5,872 | 296 |
| 31 Mar 20 | 22,742 | -5,256 | 7,157 | 264 |
| 31 Dec 19 | 20,974 | -8,106 | 7,250 | 829 |
| 30 Sep 19 | 21,723 | -11,654 | 7,802 | 1,080 |
| 30 Jun 19 | 23,074 | -14,176 | 7,764 | 1,080 |
| 31 Mar 19 | 22,398 | -13,842 | 4,406 | 2,306 |
| 31 Dec 18 | 24,370 | -13,143 | 6,609 | 1,601 |
| 30 Sep 18 | 18,340 | -8,691 | 1,246 | 1,794 |
| 30 Jun 18 | 22,832 | -5,945 | 3,335 | 1,794 |
| 31 Mar 18 | 23,683 | -9,837 | 7,734 | 1,018 |
| 31 Dec 17 | 25,635 | -11,369 | 6,438 | 2,148 |
| 30 Sep 17 | 38,032 | -9,162 | 9,851 | 4,189 |
| 30 Jun 17 | 36,241 | -9,590 | 9,360 | 4,189 |
| 31 Mar 17 | 39,366 | -4,347 | 10,045 | 3,692 |
| 31 Dec 16 | 38,353 | -2,508 | 11,819 | 2,562 |
| 30 Sep 16 | 32,799 | -6,484 | 8,952 | 3,515 |
| 30 Jun 16 | 29,337 | -8,260 | 11,130 | 3,515 |
| 31 Mar 16 | 25,017 | -11,782 | 12,383 | 3,515 |
| 31 Dec 15 | 19,689 | -12,467 | 11,362 | 3,515 |
| 30 Sep 15 | 15,167 | -10,570 | 11,542 | 3,071 |
| 30 Jun 15 | 10,910 | -9,405 | 7,301 | 3,071 |
| 31 Mar 15 | 7,943 | -7,297 | 4,550 | 2,293 |
| 31 Dec 14 | 9,132 | -6,446 | 2,787 | 3,071 |
Quality Earnings: A159910 is currently unprofitable.
Growing Profit Margin: A159910 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A159910 is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare A159910's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A159910 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-4.5%).
Return on Equity
High ROE: A159910 has a negative Return on Equity (-41.57%), as it is currently unprofitable.